Cardiff Oncology to Present at Upcoming Investor Conferences in September
Cardiff Oncology, Inc. (Nasdaq: CRDF) will participate in the Baird Global Healthcare Conference and the H.C. Wainwright 24th Annual Global Investment Conference in New York, NY. The Baird Conference is on September 13, 2022, featuring a fireside chat at 2:00 PM ET. The H.C. Wainwright Conference is on September 14, 2022, with a corporate presentation at the same time. The company focuses on developing novel therapies for various cancers, leveraging PLK1 inhibition through their lead asset, onvansertib. More details are available on their official website.
- None.
- None.
SAN DIEGO, Sept. 8, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will present and participate in 1x1 investor meetings at the Baird Global Healthcare Conference and the H.C. Wainwright 24th Annual Global Investment Conference taking place in New York, NY, on September 13 – 14, 2022, and September 12 – 14, 2022, respectively.
Details on the presentations can be found below.
Baird Global Healthcare Conference
Location: | InterContinental New York Barclay |
Date: | Tuesday, September 13, 2022 |
Time: | 2:00 PM ET |
Format: | Fireside Chat |
H.C. Wainwright 24th Annual Global Investment Conference
Location: | Lotte New York Palace Hotel |
Date: | Wednesday, September 14, 2022 |
Time: | 2:00 PM ET |
Format: | Corporate Presentation |
Webcast Link: |
A replay of the H.C. Wainwright presentation will be available by visiting the "Events" section of the Cardiff Oncology website after its conclusion.
Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers. Our lead asset is onvansertib, a PLK1 inhibitor we are evaluating in combination with standard-of-care (SOC) therapeutics in clinical programs targeting indications such as KRAS-mutated metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma, and metastatic castrate-resistant prostate cancer. These programs and our broader development strategy are designed to target tumor vulnerabilities in order to overcome treatment resistance and deliver superior clinical benefit compared to the SOC. For more information, please visit https://www.cardiffoncology.com.
Cardiff Oncology Contact:
James Levine
Chief Financial Officer
858-952-7670
jlevine@cardiffoncology.com
Investor Contact:
Joyce Allaire
LifeSci Advisors
212-915-2569
jallaire@lifesciadvisors.com
Media Contact:
Amy Jobe, Ph.D.
LifeSci Communications
315-879-8192
ajobe@lifescicomms.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/cardiff-oncology-to-present-at-upcoming-investor-conferences-in-september-301620251.html
SOURCE Cardiff Oncology, Inc.
FAQ
What is the date of Cardiff Oncology's presentation at the Baird Global Healthcare Conference?
Where is the H.C. Wainwright 24th Annual Global Investment Conference being held?
What time is Cardiff Oncology's corporate presentation at the H.C. Wainwright Conference?
What therapeutic approach does Cardiff Oncology use in its development strategy?
What is the ticker symbol for Cardiff Oncology?
